We are live on ! Find out more
SGTX

Sigilon Therapeutics, Inc. Common Stock

Delisted

SGTX was delisted on the 10th of August, 2023.

45 hedge funds and large institutions have $109M invested in Sigilon Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

186% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 7

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

13% less funds holding

Funds holding: 5245 (-7)

41% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 17

48% less capital invested

Capital invested by funds: $209M → $109M (-$99.8M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $246K

Holders
45
Holders Change
-7
Holders Change %
-13.46%
% of All Funds
0.79%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
20
Reduced
7
Closed
17
Calls
Puts
$246K
Net Calls
-$246K
Net Calls Change
-$246K
Name Holding Trade Value Shares
Change
Change in
Stake
Victory Capital Management
51
Victory Capital Management
Texas
-$657K -4,707 Closed
PTC
52
Philadelphia Trust Company
Pennsylvania
-$483K -3,462 Closed
Two Sigma Investments
53
Two Sigma Investments
New York
-$352K -2,522 Closed
Walleye Capital
54
Walleye Capital
New York
-$344 -2,465 Closed
JF
55
Jump Financial
Illinois
-$163K -1,169 Closed
Citadel Advisors
56
Citadel Advisors
Florida
-$85.5K -1,111 Closed
D.E. Shaw & Co
57
D.E. Shaw & Co
New York
-$155K -1,111 Closed
Ensign Peak Advisors
58
Ensign Peak Advisors
Utah
-$145K -1,038 Closed
TI
59
Trexquant Investment
Connecticut
-$121K -869 Closed
PA
60
Parallel Advisors
California
-$1K -7 Closed
S
61
SignatureFD
Georgia
-$1K -5 Closed
EI
62
Ellevest Inc
New York
+$77 +1 New

SGTX Hedge Fund Activity: Q3 2021 in Review

45 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Sigilon Therapeutics, Inc. Common Stock (SGTX) for Q3 2021, worth a combined $109M — down 48% from $209M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of SGTX and 10 opened new positions — a net loss of 7 holders — while 7 trimmed existing stakes and 20 added.

The largest buyer was BlackRock, adding an estimated $1.99M. The largest seller was Wellington Management Group, exiting entirely with an estimated $6.66M sold.

  • 45 institutional investors held Sigilon Therapeutics, Inc. Common Stock (SGTX) as of Q3 2021, down from 52 in Q2 2021.
  • Funds reported $109M of Sigilon Therapeutics, Inc. Common Stock stock for Q3 2021, down 48% quarter-over-quarter.
  • 10 funds opened new Sigilon Therapeutics, Inc. Common Stock positions in Q3 2021 and 17 closed out, a net change of -7 holders.
  • The largest Sigilon Therapeutics, Inc. Common Stock buyer in Q3 2021 was BlackRock, an estimated $1.99M added.
  • The largest Sigilon Therapeutics, Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $6.66M sold.

Based on aggregated 13F filings for Q3 2021.